天新药业 (603235)
JiangXi Tianxin Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 43778.00
- Circulating A-Shares(W): 14706.52
- Earnings Per Share(RMB): 1.0600
- Net Assets Per Share(RMB): 10.9307
- Operating Revenue(W RMB): 163094.53
- Total Profit(W RMB): 55164.51
- **Net Profit Attributable to Parent(W RMB) **: 46030.39
- Net Profit Growth Rate(%): -6.91
- Weighted Return on Equity(%): 9.7600
- Operating Cash Flow Per Share(RMB): 1.1210
- Undistributed Profit Per Share(RMB): 4.9952
- Capital Reserve Per Share(RMB): 4.5726
2. Main Business
The main business covers:
- Research, development, production and sales of monomer vitamin products.
3. Company Basic Information
- Company Name: Jiangxi Tianxin Pharmaceutical Co., Ltd.
- Listing Date: 2022-07-12
- Industry: Pharmaceuticals & Healthcare - Chemical Pharmaceuticals
- Address: Industrial Park, Leping City, Jingdezhen City, Jiangxi Province
- Website: https://www.txpharm.com/
- Company Profile: The company was established as a joint stock company through the overall transformation of Tianxin Co., Ltd. On November 20, 2017, Tianxin Co., Ltd. held a shareholders' meeting and agreed to the overall transformation into a joint stock company. On the same day, Tianxin Pharmaceutical held its founding meeting and first shareholders' meeting, reviewing and approving the overall transformation into a joint stock company through net asset conversion, and the plan for Tianxin Pharmaceutical's total share capital and net asset conversion. On November 20, 2017, Lixin issued the "Capital Verification Report" (Xin Hui Shi Bao Zi [2017] No. ZA16362), verifying that the company's registered capital had been fully paid. On November 23, 2017, the Jingdezhen Market and Supervision Administration issued the "Business License" (Unified Social Credit Code: 91360200767014627G) to the company.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shenzhen Tonghe Private Securities Investment Fund Management Co., Ltd. - Tonghe Macro Hedge Phase I Private Securities Investment Fund | Private Securities Investment Fund | 42.50 | 0.29 |
| 2 | ChinaAMC CSI 800 Index Enhanced Securities Investment Fund Class A | Fund | 0.34 | 0.00 |
5. Concept Sectors
- Vitamins
- High-Performance Stocks
- Below IPO Price
- New Private Placements
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information